XNASROIV
Market cap8.71bUSD
Dec 23, Last price
11.97USD
1D
3.46%
1Q
2.40%
IPO
15.10%
Name
Roivant Sciences Ltd
Chart & Performance
P/E
2.00
P/S
69.82
EPS
5.97
Div Yield, %
0.07%
Shrs. gr., 5y
31.01%
Rev. gr., 5y
121.82%
Revenues
125m
+103.65%
Net income
4.35b
P
CFO
-765m
L-9.26%
Earnings
Feb 11, 2025
Profile
Montes Archimedes Acquisition Corp. focuses to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was founded in 2020 and is based in Menlo Park, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | |
| Income | ||||||
Revenues | 124,795 103.65% | 61,280 10.84% | 55,286 132.34% | |||
Cost of revenue | 529,700 | 1,138,849 | 1,267,034 | |||
Unusual Expense (Income) | ||||||
NOPBT | (404,905) | (1,077,569) | (1,211,748) | |||
NOPBT Margin | ||||||
Operating Taxes | 22,224 | 5,190 | 369 | |||
Tax Rate | ||||||
NOPAT | (427,129) | (1,082,759) | (1,212,117) | |||
Net income | 4,348,926 -453.56% | (1,230,024) 33.10% | (924,116) 2.65% | |||
Dividends | (6,000) | |||||
Dividend yield | 0.07% | |||||
Proceeds from repurchase of equity | 438,555 | 371,957 | 313,424 | |||
BB yield | -5.01% | -7.07% | -9.47% | |||
| Debt | ||||||
Debt current | 21,893 | 52,413 | 11,398 | |||
Long-term debt | 535,014 | 494,160 | 346,359 | |||
Deferred revenue | 13,740 | |||||
Other long-term liabilities | 29,339 | 80,578 | 53,095 | |||
Net debt | (6,231,919) | (1,449,859) | (2,042,111) | |||
| Cash flow | ||||||
Cash from operating activities | (765,268) | (843,393) | (677,729) | |||
CAPEX | (1,382) | (12,690) | (17,436) | |||
Cash from investing activities | 5,203,623 | (44,269) | 303,295 | |||
Cash from financing activities | 419,364 | 499,462 | 306,792 | |||
FCF | (400,742) | (1,088,147) | (1,222,038) | |||
| Balance | ||||||
Cash | 6,541,073 | 1,692,115 | 2,074,034 | |||
Long term investments | 247,753 | 304,317 | 325,834 | |||
Excess cash | 6,782,586 | 1,993,368 | 2,397,104 | |||
Stockholders' equity | 1,052,037 | (3,325,550) | (2,360,180) | |||
Invested Capital | 5,925,580 | 5,494,577 | 4,771,632 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 831,049 | 712,791 | 669,753 | |||
Price | 10.54 42.82% | 7.38 49.39% | 4.94 -49.49% | |||
Market cap | 8,759,261 66.51% | 5,260,398 58.99% | 3,308,582 51.93% | |||
EV | 3,007,290 | 4,260,360 | 1,670,961 | |||
EBITDA | (382,869) | (1,058,712) | (1,205,816) | |||
EV/EBITDA | ||||||
Interest | 34,778 | 27,968 | 7,041 | |||
Interest/NOPBT | ||||||